학술논문

Pancreatic cancer among Pacific Islanders: a comprehensive analysis of an understudied racial group.
Document Type
Article
Source
Ethnicity & Health. Jul2023, Vol. 28 Issue 5, p650-660. 11p. 4 Charts, 1 Graph.
Subject
*PANCREATIC tumors
*STATISTICS
*DIVERSITY & inclusion policies
*CONFIDENCE intervals
*MULTIVARIATE analysis
*RACE
*REGRESSION analysis
*TREATMENT effectiveness
*COMPARATIVE studies
*PACIFIC Islanders
*SYMPTOMS
*KAPLAN-Meier estimator
*SURVIVAL analysis (Biometry)
*DESCRIPTIVE statistics
*MEDICAID
*PROPORTIONAL hazards models
*EVALUATION
Language
ISSN
1355-7858
Abstract
Racial disparities in care and outcome have been demonstrated for several cancers, but it is not clear that a similar discrepancy exists for pancreatic cancer. Furthermore, there are limited data describing the pancreatic cancer experience of Pacific Islanders. The primary objective of this study was to analyze the clinical characteristics, treatment, and outcomes of Pacific Islander patients with pancreatic cancer. We obtained data for a consecutive sample of pancreatic adenocarcinoma patients who presented to the largest hospital in Hawaii from 1 January 2000, through 31 December 2019. Analyses were performed for the entire population and separately for patients who had their cancer resected. Overall survival was calculated by the Kaplan–Meier method. Cox proportional hazards regression models were constructed to determine the prognostic capacity of clinical and pathologic factors. A total of 1040 patients were included in the final analysis. Pacific islanders presented at a significantly younger age compared to Whites or Asians and had the highest Medicaid rate. There were no statistically significant racial differences in stage at presentation or treatments. We did not demonstrate an association between race and survival on univariate analysis, nor after adjusting for demographic and tumor factors. Age, stage, and treatment were significantly associated with survival for both univariate and multivariate analyses. We did not demonstrate disparate outcomes among Pacific Islanders with pancreatic cancer. This is likely due in part to the absence of a screening test and the notable poor prognosis of pancreatic adenocarcinoma. Furthermore, equity in treatment may have contributed to racial parity in survival. [ABSTRACT FROM AUTHOR]